Liftstream is an executive search recruitment company in the life sciences sector
Onyx deal signals broader interest in orphan drugs
Authored by Karl Simpson
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases
Tagged Aegerion, Alexion, Amgen, BioMarin, Bloomberg, Breakthrough Therapy, Catalyst Pharmaceutical Partners, Chiesi, Chiesi Farmaceutici, EMA, FDA, Flemming Ornskov, Human Genetic Therapies, Jean-Jacques Bienaimé, Kamada, Kyprolis, life sciences, lysosomal storage diseases, M&A, Nexavar, NPS Pharmaceuticals, Onyx, Orphan drugs, pharmaceutical industry, rare diseases, regenerative medicine, Roche, San Francisco, Sarepta, Shire, speciality pharma, Ugo di Francesco, uniQure, Zymenex
Leave a comment
UK aiming to boost regenerative medicine
Authored by James Sheppard
Posted in M&A Finance and Funding
Tagged cell sorter, Cell Therapy, commercialisation, David Willets, development, funding, London Biotech, One Nucleus, Oxford Biotech, regenerative medicine, research, science, Scottish Centre for Regenerative Medicine, stem cell research, Stevenage Biotech, UCL Institute of Ophthalmology, UK, UK government, UK Regenerative Medicine Platform, UKRMP
Leave a comment
Funding successes allow Promethera to look to clinical data in 2013
Authored by James Sheppard
Posted in Orphan Drugs and Rare Diseases
Tagged Allogenic Liver Cells, Boehringer Ingelheim, clinical, Crigler-Najjar, Eric Halioua, Etienne Sokal, funding, GMP, HepStem, Liftstream, Liftstream Rare Disease Day, Liver Fibrosis, Phenylketonuria, Promethera Bioscience, rare disease day, RDD13, regenerative medicine, Shire, Stem Cells
1 Comment